{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:47:24Z","timestamp":1789958844554,"version":"4.0.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22bm0104001"],"award-info":[{"award-number":["JP22bm0104001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22bm1004001"],"award-info":[{"award-number":["JP22bm1004001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ck0106741"],"award-info":[{"award-number":["JP22ck0106741"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ymthe.2026.04.036","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:43:55Z","timestamp":1778597035000},"page":"4758-4777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["IL-15 and IL-21 synergy improves anti-tumor efficacy of iPSC-derived cytotoxic T cells in solid tumors"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7692-3851","authenticated-orcid":false,"given":"Akihiro","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7179-5945","authenticated-orcid":false,"given":"Masazumi","family":"Waseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-4586","authenticated-orcid":false,"given":"Shin","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.04.036_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 Challenges in Cancer Immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.04.036_bib2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2026.04.036_bib4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1533033819831068","article-title":"The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review","volume":"18","author":"Zhang","year":"2019","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.ymthe.2026.04.036_bib6","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.04.036_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.04.036_bib8","first-page":"669","article-title":"FDA approves first CAR T therapy","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.04.036_bib9","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2026.04.036_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology Meets Immunology: The Cancer-Immunity Cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.04.036_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T Cell Therapy for Solid Tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ymthe.2026.04.036_bib12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib13","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/imr.12644","article-title":"The role of cytokines in T-cell memory in health and disease","volume":"283","author":"Raeber","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2026.04.036_bib14","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1158\/0008-5472.CAN-12-2027","article-title":"Role of Chemokines and Chemokine Receptors in Shaping the Effector Phase of the Antitumor Immune Response","volume":"72","author":"Franciszkiewicz","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.04.036_bib15","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","article-title":"Chemokines and the immune response to cancer","volume":"54","author":"Ozga","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.04.036_bib16","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nri2580","article-title":"New insights into the regulation of T cells by \u03b3c family cytokines","volume":"9","author":"Rochman","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib17","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1182\/blood-2009-09-241398","article-title":"IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell\u2013mediated rejection of systemic lymphoma in immunodeficient mice","volume":"115","author":"Markley","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.04.036_bib18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jaci.2010.11.050","article-title":"Interleukins, from 1 to 37, and interferon-\u03b3: Receptors, functions, and roles in diseases","volume":"127","author":"Akdis","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ymthe.2026.04.036_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd.2016.245","article-title":"Induced pluripotent stem cell technology: a decade of progress","volume":"16","author":"Shi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.04.036_bib21","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.stem.2018.10.005","article-title":"Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy","volume":"23","author":"Minagawa","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2026.04.036_bib22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.stem.2012.11.002","article-title":"Generation of Rejuvenated Antigen-Specific T Cells by Reprogramming to Pluripotency and Redifferentiation","volume":"12","author":"Nishimura","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2026.04.036_bib23","first-page":"24","article-title":"Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells","volume":"7","author":"Ueda","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2026.04.036_bib24","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41467-020-20658-3","article-title":"A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy","volume":"12","author":"Iriguchi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.04.036_bib25","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1016\/j.ymthe.2021.05.016","article-title":"Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy","volume":"29","author":"Kawai","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.036_bib26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc1802","article-title":"Common markers of proliferation","volume":"6","author":"Whitfield","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2026.04.036_bib27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3\u2013Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2026.04.036_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.693016","article-title":"CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities","volume":"12","author":"Fischer","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.627764","article-title":"Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction","volume":"12","author":"Hong","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.04.036_bib31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","article-title":"Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity","volume":"32","author":"Griffith","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib32","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2026.04.036_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ymthe.2026.04.036_bib34","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell\u2013like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.04.036_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.738456","article-title":"Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors","volume":"12","author":"Ghahri-Saremi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib37","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.4049\/jimmunol.180.4.2158","article-title":"STAT1 Signaling in CD8 T Cells Is Required for Their Clonal Expansion and Memory Formation Following Viral Infection In Vivo","volume":"180","author":"Quigley","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T memory stem cells in health and disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.04.036_bib39","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: building the ultimate antitumour T cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2026.04.036_bib40","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.immuni.2011.11.006","article-title":"Keeping STATs on Memory CD8+ T Cells","volume":"35","author":"Olson","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.04.036_bib41","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20041057","article-title":"Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function","volume":"201","author":"Zeng","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.04.036_bib42","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1078-0432.CCR-23-1872","article-title":"Cooperative Armoring of CAR and TCR T Cells by T Cell\u2013Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy","volume":"30","author":"Nguyen","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.04.036_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2017.10.002","article-title":"Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms","volume":"322","author":"Davoodzadeh Gholami","year":"2017","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib44","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3389\/fimmu.2018.01718","article-title":"NOTCH Signaling in T-Cell-Mediated Anti-Tumor Immunity and T-Cell-Based Immunotherapies","volume":"9","author":"Kelliher","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15338","article-title":"Notch-mediated conversion of activated T cells into stem cell memory-like T cells for adoptive immunotherapy","volume":"8","author":"Kondo","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.04.036_bib46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/nm.3784","article-title":"Notch signaling maintains T cell memories","volume":"21","author":"Miller","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.04.036_bib47","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40425-017-0230-9","article-title":"Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment","volume":"5","author":"Scarf\u00f2","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.04.036_bib48","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.4049\/jimmunol.178.8.4786","article-title":"Profound Enhancement of the IL-12\/IL-18 Pathway of IFN-\u03b3 Secretion in Human CD8+ Memory T Cell Subsets via IL-15","volume":"178","author":"Smeltz","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib49","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12967-015-0451-y","article-title":"Focused ultrasound-induced blood\u2013brain barrier opening to enhance interleukin-12 delivery for brain tumor immunotherapy: a preclinical feasibility study","volume":"13","author":"Chen","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.04.036_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.04.036_bib51","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.04.036_bib52","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192203","article-title":"Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression","volume":"218","author":"Lanitis","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.04.036_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001647","article-title":"IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy","volume":"9","author":"Chen","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.04.036_bib54","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132000","article-title":"Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3\u2013CD8+ T cells","volume":"5","author":"Deng","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.04.036_bib55","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/mt.2008.249","article-title":"Local IL-21 Promotes the Therapeutic Activity of Effector T cells by Decreasing Regulatory T Cells Within the Tumor Microenvironment","volume":"17","author":"Kim-Schulze","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.036_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.689270","article-title":"Tertiary Lymphoid Structures in Cancer: The Double-Edged Sword Role in Antitumor Immunity and Potential Therapeutic Induction Strategies","volume":"12","author":"Kang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.674375","article-title":"Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling","volume":"12","author":"Johansson-Percival","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib58","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ymthe.2026.04.036_bib59","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib60","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.04.036_bib61","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fphar.2015.00095","article-title":"Improving the safety of cell therapy with the TK-suicide gene","volume":"6","author":"Greco","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib62","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/hum.2018.180","article-title":"A Cetuximab-Mediated Suicide System in Chimeric Antigen Receptor\u2013Modified Hematopoietic Stem Cells for Cancer Therapy","volume":"30","author":"Kao","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.04.036_bib63","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib64","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.stem.2025.05.007","article-title":"Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy","volume":"32","author":"Hosking","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2026.04.036_bib65","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.stem.2022.06.014","article-title":"EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity","volume":"29","author":"Jing","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2026.04.036_bib66","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ymthe.2026.01.020","article-title":"Feeder-free generation of CD4 single-positive helper T cells from human iPSCs via stage-specific modulation of Notch and TCR Signaling","volume":"34","author":"Kawai","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.036_bib67","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.4049\/jimmunol.1302779","article-title":"The Fli-1 Transcription Factor Regulates the Expression of CCL5\/RANTES","volume":"193","author":"Lennard Richard","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.036_bib68","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/art.37819","article-title":"Tumor necrosis factor \u03b1\u2013 and interleukin-1\u03b2\u2013dependent induction of CCL3 expression by nucleus pulposus cells promotes macrophage migration through CCR1","volume":"65","author":"Wang","year":"2013","journal-title":"Arthritis Rheum."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626003011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626003011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:36:02Z","timestamp":1786073762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626003011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":68,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1525001626003011"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.04.036","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-15 and IL-21 synergy improves anti-tumor efficacy of iPSC-derived cytotoxic T cells in solid tumors","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}